Entrada Therapeutics Inc Sustainability Reports

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing endosomal escape vehicle (EEV) therapeutics. Its pipeline targets intracellular delivery of oligonucleotide, antibody, and enzyme-based programs to treat neuromuscular diseases.

Sector: Professional & technical services

Country: United States

Exchange: Nasdaq

FIGI: BBG00MTSMC25

3 reports from 2022 to 2024

• Entrada Therapeutics Inc 2024 Annual Report to Securityholders
• Entrada Therapeutics Inc 2023 Annual Report to Securityholders
• Entrada Therapeutics Inc 2022 Annual Report to Securityholders